British deeptech startup Nanovery has achieved a significant advance, with the grant of the first patent in the UK for its unique DNA nanorobot platform.
This disruptive technology simplifies the detection of essential markers of diseases such as cancer and could accelerate the development of novel medications, including RNA therapeutics. Following recent breakthroughs that have optimised the test, the company is in talks with several potential partners to deliver pilot studies aimed at demonstrating its efficacy for multiple applications.
Read the full article at Startups Magazine.
This disruptive technology simplifies the detection of essential markers of diseases such as cancer and could accelerate the development of novel medications, including RNA therapeutics. Following recent breakthroughs that have optimised the test, the company is in talks with several potential partners to deliver pilot studies aimed at demonstrating its efficacy for multiple applications.
Read the full article at Startups Magazine.